544 related articles for article (PubMed ID: 8751209)
1. Serum hyaluronate predicts response to interferon-alpha therapy in patients with chronic hepatitis C.
Ueno T; Inuzuka S; Sata M; Koh H; Tamaki S; Kin M; Sugawara H; Sakata R; Torimura T; Tanikawa K
Hepatogastroenterology; 1995; 42(5):522-7. PubMed ID: 8751209
[TBL] [Abstract][Full Text] [Related]
2. Changes in serum fibrogenesis markers during interferon therapy for chronic hepatitis type C.
Ishibashi K; Kashiwagi T; Ito A; Tanaka Y; Nagasawa M; Toyama T; Ozaki S; Naito M; Azuma M
Hepatology; 1996 Jul; 24(1):27-31. PubMed ID: 8707274
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of interferon-treated chronic hepatitis C and serum hepatic fibrosis markers.
Ueno T; Ide T; Hashimoto O; Uchimura Y; Torimura T; Kumashiro R; Inuzuka S; Sata M
Hepatogastroenterology; 2001; 48(40):1124-8. PubMed ID: 11490815
[TBL] [Abstract][Full Text] [Related]
4. Liver fibrosis and hepatic stellate cells improvement of chronic hepatitis C patients by interferon-beta-1a with or without sustained viral response.
Rao HY; Wei L; Li J; Zhang LF; Chen HY; Zhu LM; Liu F; Sun Y; Wang H
Hepatogastroenterology; 2009; 56(90):328-34. PubMed ID: 19579592
[TBL] [Abstract][Full Text] [Related]
5. [Correlation between liver fibrosis stage and serum liver fibrosis markers in patients with chronic hepatitis B].
Ding H; Chen Y; Feng X; Liu D; Wu A; Zhang L
Zhonghua Gan Zang Bing Za Zhi; 2001 Apr; 9(2):78-80. PubMed ID: 11350682
[TBL] [Abstract][Full Text] [Related]
6. [The diagnostic value of serum hyaluronic acid, 7S domain of type IV collagen and AST/ALT ratio as markers of hepatic fibrosis in chronic hepatitis B and cirrhosis patients].
Park JH; Park CK; Kim ES; Park SY; Jo CM; Tak WY; Kweon YO; Kim SK; Choi YW
Taehan Kan Hakhoe Chi; 2003 Jun; 9(2):79-88. PubMed ID: 12824747
[TBL] [Abstract][Full Text] [Related]
7. [Serum variations of 2 markers of fibrogenesis in chronic hepatitis C treated with alpha interferon].
Soresi M; Bascone F; Agate V; Carroccio A; Barresi E; Cartabellotta A; Aragona F; Montalto G
Recenti Prog Med; 1997 Feb; 88(2):73-6. PubMed ID: 9148370
[TBL] [Abstract][Full Text] [Related]
8. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B.
Musch E; Högemann B; Gerritzen A; Fischer HP; Wiese M; Kruis W; Malek M; Gugler R; Schmidt G; Huchzermeyer H; Gerlach U; Dengler HJ; Sauerbruch T
Hepatogastroenterology; 1998; 45(24):2282-94. PubMed ID: 9951911
[TBL] [Abstract][Full Text] [Related]
9. alpha-Interferon retreatment of patients with chronic hepatitis C.
Rabinovitz M; Block G; Finkelstein SD
Am J Gastroenterol; 1996 Aug; 91(8):1523-6. PubMed ID: 8759654
[TBL] [Abstract][Full Text] [Related]
10. [Serum markers and pathological evaluation in hepatitis fibrosis of chronic hepatitis B treated with interferon alpha].
Deng L; Zhou Y; Peng X; Deng H; Deng Y; Yao J
Zhonghua Gan Zang Bing Za Zhi; 2001 Jul; 9 Suppl():66-7. PubMed ID: 11509145
[TBL] [Abstract][Full Text] [Related]
11. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
Shindo M; Ken A; Okuno T
Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
[TBL] [Abstract][Full Text] [Related]
12. Interferon therapy in HCV-positive mixed cryoglobulinaemia: viral and host factors contributing to efficacy of the therapy.
Mazzaro C; Carniello GS; Colle R; Doretto P; Mazzi G; Crovatto M; Santini GF; Tulissi P; Gregoretti M; Mazzoran L; Russo A; Silvestri F; Pozzato G
Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):343-50. PubMed ID: 9476189
[TBL] [Abstract][Full Text] [Related]
13. Treatment of chronic hepatitis C with interferon-alpha. Clinical histological and virological implications.
Olaso V; Córdoba J; Berenguer M; Prieto M; Lainez B; Argüello L; Valverde J; Pascual S; Gobernado M; Berenguer J
Rev Esp Enferm Dig; 1997 Jul; 89(7):531-50. PubMed ID: 9265839
[TBL] [Abstract][Full Text] [Related]
14. Elevation of serum type IV collagen in liver cancer as well as liver cirrhosis.
Hong WS; Hong SI; Park SY; Son Y; Lee YS; Chung YH; Yang SK; Suh DJ; Min YI
Anticancer Res; 1995; 15(6B):2777-80. PubMed ID: 8669863
[TBL] [Abstract][Full Text] [Related]
15. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
[TBL] [Abstract][Full Text] [Related]
16. Response of chronic hepatitis C to interferon-alpha treatment and relationship with iron metabolism.
Martín-Vivaldi R; Nogueras F; González A; Quintero D; Pinel LM; Castro T; Hernández A
Rev Esp Enferm Dig; 1997 Jul; 89(7):523-30. PubMed ID: 9265838
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases.
Bayraktar Y; Bayraktar M; Gurakar A; Hassanein TI; Van Thiel DH
Hepatogastroenterology; 1997; 44(14):417-25. PubMed ID: 9164512
[TBL] [Abstract][Full Text] [Related]
18. The levels of serum fibrosis marks and morphometric quantitative measurement of hepatic fibrosis.
Xie SB; Yao JL; Zheng SS; Yao CL; Zheng RQ
Hepatobiliary Pancreat Dis Int; 2002 May; 1(2):202-6. PubMed ID: 14607739
[TBL] [Abstract][Full Text] [Related]
19. [Serologic response against hepatitis C virus as a predictive factor to the treatment with interferon].
Garrido A; Lepe JA; Guerrero FJ; Palomo S
Enferm Infecc Microbiol Clin; 2000 Dec; 18(10):512-5. PubMed ID: 11198002
[TBL] [Abstract][Full Text] [Related]
20. [Effect of pegylated interferon beta-1a therapy on the liver fibrosis in chronic hepatitis C: a semi-quantitative analysis].
Rao HY; Li J; Zhang LF; Chen HY; Zhu LM; Wei L; Sun Y; Wang H
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):96-100. PubMed ID: 18353212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
